Lyell Immunopharma

Lyell Immunopharma is a clinical-stage T-cell reprogramming company developing cell therapies for solid tumors and hematologic cancers. Its pipeline includes CAR T-cell candidates such as ronde-cel (rondecabtagene autoleucel, LYL314), a CD19/CD20 dual-targeting CAR T-cell product for B-cell lymphomas, and LYL273, a GCC-targeted CAR T-cell product for colorectal cancer. The company uses its proprietary technologies to improve T-cell durability and function, with the aim of delivering curative treatments for patients with cancer.